LC-MS raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-11-14 and is reviewed periodically as new material appears.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
The peer-reviewed record is dominated by small early-phase studies, case reports and pharmacovigilance summaries rather than large randomised trials. Papers typically examine tanning response, receptor selectivity or patterns of reported adverse events. Many note that participants obtained the peptide outside a clinical setting, which limits verification of composition and administered amount. Reported events vary widely, and causality is frequently unclear because the identity and purity of self-sourced material are unknown. Open questions include whether repeated melanocortin receptor stimulation produces cumulative effects, and how often label claims match actual content.
Identification in laboratories relies on reversed-phase liquid chromatography coupled with tandem mass spectrometry, with product-ion spectra compared against a certified reference standard. High-resolution mass spectrometry supplies accurate mass confirmation, and peptide mapping after enzymatic digestion separates melanotan II from closely related analogues. Quantitation of seized material is complicated by unknown counter-ions and residual trifluoroacetate left from purification. Immunoassays raised against alpha-melanocyte-stimulating hormone can cross-react, so chromatographic confirmation is normally required. Urinary detection windows are short, and reported limits of detection differ substantially between laboratories.
Melanotan II holds no marketing authorisation from the Food and Drug Administration, the European Medicines Agency, the UK Medicines and Healthcare products Regulatory Agency or Australia's Therapeutic Goods Administration. Products sold under that name are treated as unapproved new drugs, and their sale or import is prohibited in several jurisdictions. Other countries classify the peptide as a prescription-only medicine or place it among controlled substances, so the legal position changes with the destination market. No pharmacopoeial monograph supplies an official specification, because the material is not a licensed pharmaceutical. Consequently, products offered online are not manufactured to a shared public standard.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic cyclic heptapeptide | Analog of alpha-MSH with an internal lactam bridge |
| Molecular weight | Approximately 1024 daltons | Free base value; salt forms differ |
| Appearance | White to off-white powder | Usually supplied as a lyophilized solid |
| Solubility | Freely soluble in water | Poorly soluble in nonpolar solvents |
| Typical storage | −20 °C, dry, protected from light | Repeated freeze-thaw cycles degrade peptides |
Published pharmacokinetic information is limited and comes mainly from small studies rather than registrational trials. Plasma half-life is usually described as short, on the order of tens of minutes, followed by rapid tissue distribution and clearance of the intact peptide. Metabolites and low concentrations of parent compound have been reported in urine, a detail relevant to anti-doping and forensic testing. Whether repeated exposure changes receptor sensitivity or clearance over time remains an open question. Values differ noticeably between analytical assays, so published numbers should be read as approximate rather than definitive.
Melanotan II is a synthetic cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, corresponding to a molecular formula of C50H69N15O9 and a monoisotopic mass near 1024 daltons. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, a peptide hormone produced by cleavage of proopiomelanocortin. A lactam bridge between the aspartate and lysine side chains closes the ring, and the C-terminal amide removes a free carboxyl group. Both modifications increase resistance to enzymatic degradation compared with the linear parent hormone. Four substitutions distinguish it from afamelanotide, the linear analogue studied under the name melanotan I.
Verification of a purchased sample requires documentation linking a batch to a certificate of analysis, and that document should be read for the methods used rather than the headline purity figure. A single chromatographic percentage does not establish identity. Independent laboratories can perform identity and content assays, but no such test establishes that a product is suitable for human use. Claims about efficacy rest largely on small, early studies rather than on replicated controlled trials, and that gap remains open.
Identity testing for a cyclic peptide of this size usually relies on reversed-phase high-performance liquid chromatography coupled to mass spectrometry. The mass spectrum confirms molecular weight, while the chromatographic trace indicates the proportion of related impurities. Tandem mass spectrometry can provide sequence-level information when fragmentation data are compared against a reference standard. Nuclear magnetic resonance is sometimes used to confirm the lactam bridge, although it requires more material and greater operator expertise than routine chromatographic methods.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Regulatory treatment varies by country. In the United States, melanotan-2 is not approved for any indication, and products marketed for human use fall outside the approved drug framework. Some other jurisdictions have placed it under prescription controls or listed it as a prohibited or restricted substance. Online listings frequently describe the material as a research chemical, a category that does not carry the same manufacturing and labelling requirements as approved medicines.
Solid peptide material is generally stable when kept cold and dry. Common practice is storage at -20 degrees Celsius or lower, with desiccant and protection from light. Repeated freeze-thaw cycles and exposure to moisture are associated with degradation, aggregation, or loss of material. Once dissolved, stability depends on solvent, concentration, and temperature, and solutions are usually treated as short-lived unless stability data support longer periods. Handling notes typically emphasise minimising time at ambient temperature.
Identity and purity are assessed with chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the target peptide from related impurities and degradation products, and the resulting retention time is compared against a reference standard. Mass spectrometry, often coupled to liquid chromatography, confirms molecular mass. Amino acid analysis or peptide mapping can provide additional sequence-level confirmation when required. Results are only as reliable as the reference materials used alongside them.
Temperature dependence: LED performance largely depends on the ambient temperature of the operating environment – or thermal management properties. Overdriving an LED in high ambient temperatures may result in overheating the LED package, eventually leading to device failure. An adequate heat sink is needed to maintain long life. This is especially important in automotive, medical, and military uses where devices must operate over a wide range of temperatures, and require low failure rates.
The 2024 New Year Honours are appointments by some of the 15 Commonwealth realms to various orders and honours to recognise and reward good works by citizens of those countries. The New Year Honours are awarded as part of the New Year celebrations at the start of January and those for 2024 were announced on 29 December 2023, on the same day as the 2022 Prime Minister's Resignation Honours. The recipients of honours are displayed as they were styled before their new honour and arranged by the country whose ministers advised Charles III on the appointments, then by the honour and by the honour's grade (i.e. Knight/Dame Grand Cross, Knight/Dame Commander, etc.), and then by divisions (i.e. Civil, Diplomatic, and Military), as appropriate. The BBC reported that it had already received press releases from some recipients before the honours list was published, contrary to the "longstanding practice of modest secrecy ahead of the announcement, even though award winners will have known for weeks".
It should be clearly understood that the major role of the profession is patient care and that research, management and all the other aspects will come as side issues and not be the predominating factor in the career path. The work of biomedical scientists and clinical scientists have impact on the diagnosis and treatment of almost every patient admitted to hospitals in the United Kingdom. The United Kingdom is facing a shortage of qualified clinical and biomedical scientists. The Royal College of Pathologists and the Royal College of Physicians have pointed out the need for increased government funding for medical training programs to prevent diagnostic facilities and medical infrastructure from being overwhelmed. MSF claims that these workers have lost out financially since the decision of the then health minister Kenneth Clarke to exclude them from the pay review body in 1984.
=== N05CA Barbiturates, plain === N05CA01 Pentobarbital N05CA02 Amobarbital N05CA03 Butobarbital N05CA04 Barbital N05CA05 Aprobarbital N05CA06 Secobarbital N05CA07 Talbutal N05CA08 Vinylbital N05CA09 Vinbarbital N05CA10 Cyclobarbital N05CA11 Heptabarbital N05CA12 Reposal N05CA15 Methohexital N05CA16 Hexobarbital N05CA19 Thiopental N05CA20 Ethallobarbital N05CA21 Allobarbital N05CA22 Proxibarbal N05CA23 Crotylbarbital N05CA24 Phenobarbital N05CA25 Propallylonal N05CA26 Bromallylmethylbutylbarbituric acid
Sources: en.wikipedia.org
==== Sucrose treatment ==== Identical to PEG treatment process but sucrose is used instead of PEG solution. The water inside the cell walls of the wood is replaced by sucrose, rather than PEG. Originally recommended as a low-cost method for treating waterlogged wood, sucrose treatments are inconsistent in how much shrinkage they prevent, especially for severely degraded wood.
An FDA category that refers to medications used to treat diseases and conditions that occur rarely. There is little financial incentive for the pharmaceutical industry to develop medications for these diseases or conditions. Orphan drug status, however, gives a manufacturer specific financial incentives to develop and provide such medications. (NLM) Outcome
The substituent name for a ring compound is cyclo. The indication (substituent name) for a six carbon chain is hex. The chemical ending for a single bonded carbon chain is ane. The chemical ending for an alcohol is ol. The two chemical endings are combined for an ending of anol indicating a single bonded carbon chain with an alcohol attached to it.
=== Charge-exchange chemical ionization === This is also similar to CI and the difference lies in the production of a radical cation with an odd number of electrons. The reagent gas molecules are bombarded with high energy electrons and the product reagent gas ions abstract electrons from the analyte to form radical cations. The common reagent gases used for this technique are toluene, benzene, NO, Xe, Ar and He. Careful control over the selection of reagent gases and the consideration toward the difference between the resonance energy of the reagent gas radical cation and the ionization energy of the analyte can be used to control fragmentation. The reactions for charge-exchange chemical ionization are as follows.
=== Muscle mass === Researchers are still debating whether the more noticeable muscles are larger in size as well. It should be clarified, though, that muscle mass is not the same as muscle strength. Some say that human growth hormone will build muscle mass through raised insulin-like growth factors levels leading to heightened protein synthesis without any side effects while other researchers argue that there have been no such findings on young healthy adults. The second argument is more supported by research discoveries that HGH affects muscle protein synthesis no differently than a placebo does.
Sources: en.wikipedia.org
== The Journey to South America == On 5 June 1799, the Pizarro departed from the port of La Coruña after a period of delay caused by unfavorable weather. The ship, commanded by Captain Cagigal, left in the early afternoon and encountered difficulties navigating the harbor due to contrary winds, nearly running aground before eventually clearing the port. The vessel passed Castle San Antonio and the Tower of Hercules by the evening, then altered its course to avoid a British naval squadron operating offshore, a precaution necessitated by ongoing hostilities and blockades associated with the European wars of the period. Spain, originally allied with Britain and other monarchies against revolutionary France, had made peace with France in 1795. If the Pizarro had been captured at sea, the ship would likely have been taken to Portugal, a British ally, resulting in the loss of passage for the expedition’s civilian passengers to the New World. During the voyage, Humboldt and Bonpland initiated scientific work, including the use of a dip needle to measure the Earth’s magnetic inclination and water-temperature readings, confirming previous observations by Franklin and Williams regarding ocean temperatures. The Pizarro sailed past Cape Finisterre and, on 8 June 1799, encountered an English squadron along the coast, prompting a change in course. The ship continued past Cape St. Vincent, a historic site for European maritime exploration. On 11 June 1799, the ship observed a large school of jellyfish in the Atlantic.
Hancock, David (2001). The Mastiffs: The Big Game Hunters – Their History, Development and Future. Ducklington, Oxon: Charwynne Dog Features. ISBN 9780951780114. Fogle, Bruce (2009). The Encyclopedia of the Dog. New York: DK Publishing. ISBN 978-0-7566-6004-8. Encyclopædia Britannica (2019). "Mastiff: breed of dog". www.britannica.com. Encyclopædia Britannica, Inc. Retrieved 9 September 2019. Parker, Heidi G. (2012). "Chapter 3: The history and relationship of dog breeds". In Ostrander, Elaine A.; Ruvinsky, Anatoly (eds.). The Genetics of the Dog. Wallingford, Oxfordshire: CAPI books. pp. 38–53. ISBN 9781845939403. Oxford Dictionaries (2019). "Mastiff". Lexico.com. Oxford University Press. Retrieved 9 September 2019. Wynn, M. B. (1886). History of the Mastiff: Gathered from Sculpture, Pottery, Carvings, Paintings and Engravings. Melton Mowbray, William Loxley. ISBN 978-1-4465-4892-9. {{cite book}}: ISBN / Date incompatibility (help) Young, Amy; Bannasch, Danika (2007). "Chapter 4: Morphological variation in the dog". In Ostrander, Elaine A.; Giger, Urs; Lindblad-Toh, Kerstin (eds.). The Dog and its Genome. Cold Spring Harbor, New York: Cold Spring Harbor Laboratory Press. pp. 47–66. ISBN 9780879697815.
== Legacy == In 2000, Player was voted "Sportsman of the Century" in South Africa. In 1966, he was awarded the Bob Jones Award, the highest honour given by the United States Golf Association in recognition of distinguished sportsmanship in golf. He was inducted into the World Golf Hall of Fame in 1974. The "Gary Player – A Global Journey" exhibition was launched by the Hall of Fame as of March 2006. In 2000, Golf Digest magazine ranked Player as the eighth greatest golfer of all time. On 10 April 2009, he played for the last time in the Masters, where he was playing for his record 52nd time – every year since 1957 except for 1973, when he was recovering from surgery. At age 73 on 23 July 2009, Player competed in the Senior British Open Championship at Sunningdale Golf Club, 53 years after capturing his maiden European Tour victory at the Berkshire venue. Augusta National Golf Club and the Masters announced on 5 July 2011 that Player had been invited to join Jack Nicklaus and Arnold Palmer as an honorary starter. The Big Three were reunited in this capacity starting with the 2012 tournament. In July 2013, Player became the oldest athlete ever to pose nude in ESPN The Magazine's annual Body Issue to inspire people to keep looking after themselves throughout their lives whatever their age.
The game's scope suffered from content not being removed when necessary; other components would be endlessly refined without being finalized, preventing the developers from focusing on other parts of the game system. All content additionally required approval by White Wolf and Activision. After three years of development, the game was progressing slowly, and it was unknown when it would be finished. Activision set a series of deadlines for the project's development to ensure Troika had sufficient time to effectively test the game, though these milestones were repeatedly extended, and Bloodlines eventually ran over budget. In 2003 Activision intervened, ordering that the game be ready for release in the next few months and even advancing more money to Troika to complete its work on The Temple of Elemental Evil for Atari, freeing the Troika team to work on Bloodlines exclusively. Activision eventually issued an ultimatum that the project be finished within months, on September 15, 2004. Troika delivered a version of Bloodlines on the required date; due to its scale, the game underwent three weeks of testing. Activision decided that the game was suitable for release but was contractually bound to withhold Bloodlines until after the debut of Half-Life 2 in November 2004. Troika convinced Activision to use the delay to fund further development; the additional budget was insufficient to pay all of Troika's staff, and some employees worked unpaid to complete the project.
The best known was the November 4 insurrection in Cosenza, initially motivated by hunger and the housing crisis, which quickly turned into a political struggle to remove Fascist mayor Enrico Hendrich, who was ousted by popular vote. Liberation allowed anti-fascist parties to reemerge, including the Socialist Party, the Communist Party and the Christian Democracy. The latter was a Catholic-inspired organization founded in 1942 as the heir to Don Luigi Sturzo's Italian People's Party. Peasants, who made up about 60% of the population, began a series of violent uprisings demanding better conditions, including land reform. This included the return of large-scale occupations of uncultivated land. On the other side were the elite of agrarians and large landowners, who abandoned Fascism to maintain their position. In June 1944, Victor Emmanuel III handed power to his son Umberto II of Savoy, who obtained the Lieutenancy of the Kingdom. In July, a month after the liberation of Rome, Calabrian Communist Fausto Gullo, formerly minister of Agriculture in the second Badoglio government and in subsequent administrations (second Bonomi government, third Bonomi government and Parri government), proposed a series of decrees (named after him) to help the peasant class. Among them were: sharecropping reform; grants of uncultivated land to peasants in agricultural cooperatives; compensation to farmers who took their produce to storage, (previously diverted to the black market); and the prohibition of the caporale (day laborer recruiter).
Sources: en.wikipedia.org
It is a synthetic seven-amino-acid peptide modeled on alpha-melanocyte-stimulating hormone. It carries two non-natural substitutions and a cyclic bridge that increase its stability relative to the natural hormone. It circulates as a research chemical and is not an approved medicine.
Melanotan-1, also called afamelanotide, is a shorter linear analog with a different amino acid sequence and no lactam ring. It has been evaluated in formal clinical programs, while melanotan-2 has not. The two are distinct molecules and are not interchangeable.
No. Bremelanotide is a related but distinct cyclic peptide that reached approved status for one specific clinical indication. Melanotan-2 is a separate molecule with its own sequence and properties. Shared ancestry in the melanocortin family does not make them the same substance.
Regulatory treatment varies by country. In the United States, the European Union and Australia it is an unapproved drug and its sale is restricted, while some other jurisdictions list it as prescription-only or controlled. The applicable rules depend on the country of import.